This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Eylea ® is a trademark of Bayer AG and in the US of Regeneron Pharmaceuticals, Inc. This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Sandoz, a Novartis division, is a global leader in genericpharmaceuticals and biosimilars.
Sandoz is the global leader in generic antibiotics and operates the only vertically-integrated antibiotic network left in Europe, despite fierce competition from Asia. Disclaimer This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995.
Eylea ® is a trademark of Bayer AG and in the US of Regeneron Pharmaceuticals, Inc. This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Sandoz, a Novartis division, is a global leader in genericpharmaceuticals and biosimilars.
Huebscher , non-executive board member in companies, institutions and former CEO of Solvias Group, a Swiss contract research firm, which she led between 2014 and 2021. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. The new board members are: Dr. Karen J.
“Today’s approval of the first generic for one of the most commonly prescribed complex drug-device combination products to treat asthma and COPD is another step forward in our commitment to bring generic copies of complex drugs to the market, which can improve quality of life and help reduce the cost of treatment,” said Sally Choe, Ph.D.,
We delve into the driving forces behind their successes and shed light on the groundbreaking research that has earned them a place among the elite in the pharmaceutical arena. It contains the antiviral medications nirmatrelvir and ritonavir. 12) Shanghai Pharmaceuticals By: Vincent Xie, M.Sc. billion in 2022.
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content